Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neuro-Oncology
•
Medical Oncology
•
Neurology
What factors do you take into account when deciding the length of adjuvant temozolamide in GBM?
Related Questions
For a patient with large volume glioblastoma, what do you do if they are found to have a subdural infection in the middle of chemoRT requiring repeat surgery?
How do you counsel glioblastoma multiforme patients on which types of clinical trials to pursue?
How would you approach a patient with recurrent grade 3 oligodendroglioma (MGMT-methylated, IDH mutant, 1p/19q co-deleted) 1 year after gross total resection and adjuvant chemotherapy and radiation?
Is there a role for bevacizimab (IV or IA) for steroid refractory radionecrosis for AVM?
How will you select patients with brain metastases for TTFields?
Are you offering Lutathera for multiple recurrent meningiomas?
Would patients receiving targeted therapies be eligible for TTFields for brain metastases?
What are your top takeaways in Neuro Oncology from ASCO 2025?
How do you manage follow up for patient who was diagnosed with pineal gland germinomas with drop metastatic to the spinal cord?
How would you advise a younger patient with residual/recurrent optic nerve meningioma, proceeding with radiotherapy, about the risks of malignant transformation or induction of other brain malignancies because of radiation?
